Viral replication

CVMR Succeeds in the Production of Self-Assembled Graphene Structures

Retrieved on: 
Thursday, April 30, 2020
Materials, Matter, Articles, Graphene, Emerging technologies, Monolayers, Potential applications of graphene, Virus, Replication, Graphite, Viral replication

The newly created viruses are then released from the host cell, causing the cell to break apart and die.

Key Points: 
  • The newly created viruses are then released from the host cell, causing the cell to break apart and die.
  • Scientists and engineers at CVMR exploit the viral replication process by engineering nanostructures that are compatible of replicating themselves similar to the structure and modus operandi of viruses.
  • The captured solar heat through this assembly of graphene sheets is converted to kinetic energy and ultimately to electricity.
  • CVMR Corporation was awarded two matching grants from the Ontario Centres of Excellence (OCE) in 2017 and 2018-2019 for the capture of CO2 and its conversion to graphene and graphite.

Research by Assembly Biosciences and Academic Collaborators Published in Hepatology Indicates cccDNA Turnover Time May Enable Hepatitis B Cures Following Finite Therapy

Retrieved on: 
Monday, April 6, 2020
Infectious diseases, Medical specialties, Microbiology, RTT, cccDNA, DNA, Infectious causes of cancer, Hepatitis B, HBV, Viral replication, Hepatitis

The article is entitled Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of SignatureMutation in Treated Chronic Hepatitis B Patients and is available online with open access .

Key Points: 
  • The article is entitled Rapid Turnover of HBV cccDNA Indicated by Monitoring Emergence and Reversion of SignatureMutation in Treated Chronic Hepatitis B Patients and is available online with open access .
  • It shows that cccDNA turnover occurs in months, not years as once thought, supporting the possibility of finite therapy if cccDNA replenishment can be effectively blocked.
  • Combining core inhibitors, which inhibit cccDNA establishment, with nucleos(t)ide therapy may provide a regimen that is able to more fully suppress viral replication and inhibit the establishment of new cccDNA.
  • Assembly Biosciences, Inc.is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome.